Proposed Collection; Comment Request; Customer Satisfaction With Educational Programs and Products of the National Cancer Institute, 7894-7895 [E7-2886]
Download as PDF
<![CDATA[
7894
Federal Register / Vol. 72, No. 34 / Wednesday, February 21, 2007 / Notices
National Institute on Drug Abuse
(NIDA) launched an initiative to
increase awareness of the Institute and
its mission to bring the power of science
to bear on the treatment and prevention
of drug abuse and addiction. NIDA has
been developing science education
materials for grades K–12 for use by
students, teachers, parents, school
counselors, school health educators,
school resources officers, community
organizers, and state and local
government agencies. The number of
requestors has been an average of 7,500
per year. These large numbers indicate
that the dissemination reach is
considerable. The pattern of requests
also indicates that the number of
requests increases dramatically in the
early weeks after a dissemination
activity is launched. The purpose of this
information collection is to determine
the level of use by school personnel and
community leaders who request the
NGBTS materials, and if there is a
difference in use level between those
requestors responding to a campaign
activity and those requestors who were
not reached by campaign activities. The
information will identify barriers to the
use of the materials among these
occupational groups and the
populations they serve. It will help
make the materials more productive in
raising the awareness of the harms from
substance abuse among children, youth,
and parents. It will be used to refine the
focus of the dissemination activities, so
that dissemination resources are used
more productively. The information will
be collected from requestors who have
requested NIDA NGBTS materials using
the requestor forms from the NIDA site,
from October 2003 to September 2005.
All information collection in the
evaluation will be conducted on-line.
The estimated total time for a survey is
5 minutes. Prior to the monitoring and
evaluation study, the information
collection instruments will be pilottested via telephone interview format,
with a sample of 8 individuals who
have requested these materials during
the chosen study years. The surveys will
include the following elements: (1) Use
of the NGBTS materials, (2) Opinion of
Number of
respondents
Type of respondents
the NGBTS materials, (3) Respondent
information on gender, present
occupation and its duration, (4)
Background information on the school
or Organization/Community.
Frequency of Response: This project
will be conducted once.
Affected Public: School personnel,
and Community Leaders who have
requested the NGBTS materials.
Type of Respondent: School
personnel, and Community Leaders who
have requested the NGBTS materials
from the NIDA site.
Estimated Total Annual Number of
Respondents: 400.
Estimated Number of Responses per
Respondent: 1.
Average Burden Hours per Response:
.08.
Estimated Total Annual Burden
Hours Requested: 96.0. There are no
Capital Costs to report. There are no
Operating or Maintenance Costs to
report. The estimated annualized
burden is summarized below.
Frequency of
response
Average
burden hours
per response
Estimated total
burden hours
requested
600
600
1
1
0.08
0.08
48
48
Total ..........................................................................................................
rmajette on PROD1PC67 with NOTICES
Requestors—School Personnel .......................................................................
Requestors—Community Leaders ...................................................................
1200
........................
........................
96
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(2) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (3) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
For Further Information Contact: To
request more information on the
proposed project or to obtain a copy of
the information collection plans, contact
Brian Marquis, Project Officer, National
Institute on Drug Abuse, 6001 Executive
Boulevard, Room 5216, Bethesda, MD
20892, or call non-toll-free number 301–
443–1124; fax 301–443–7397; or by email to bmarquis@nida.nih.gov.
VerDate Aug<31>2005
17:27 Feb 20, 2007
Jkt 211001
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: February 9, 2007.
Donna Jones,
Budget Officer & Acting Associate Director
for Management, National Institute on Drug
Abuse.
[FR Doc. E7–2881 Filed 2–20–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Customer Satisfaction With
Educational Programs and Products of
the National Cancer Institute
Summary: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI), the
National Institutes of Health (NIH) will
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection
Title: Customer Satisfaction with
Educational Programs and Products of
the National Cancer Institute.
Type of Information Collection
Request: EXTENSION (OMB#0925–
0526, expires 2/28/07).
Need and Use of Information
Collection: The Office of
Communications and Education (OCE)
of the National Cancer Institute (NCI) is
responsible for the design,
implementation, and evaluation of
education programs over the entire
cancer continuum, including
prevention, screening, diagnosis,
treatment, survivorship, and palliative
care; it also manages NCI initiatives that
address specific challenges in cancer
research and treatment. To help ensure
the relevance, utility, and
appropriateness of the many
educational programs and products that
OCE and NCI produce, OCE intends to
collect information on customer
E:\FR\FM\21FEN1.SGM
21FEN1
Federal Register / Vol. 72, No. 34 / Wednesday, February 21, 2007 / Notices
satisfaction with those products through
customer satisfaction surveys. By
obtaining information from customers
on the extent to which materials satisfy
their needs, OCE and NCI will be able
to systematically establish and follow a
feedback loop that provides useful
information to revise and enhance
educational programs and products so
that they attain maximum relevance,
utility, appropriateness, and impact.
Data will be collected through various
means, including telephone, mail, inperson, and web-based surveys.
Frequency of Response: On occasion.
Affected Public: Individuals or
households, organizations involved in
providing health care services.
7895
Type of Respondents: Health care
consumers of NCI educational programs
or products, including cancer patients
and families, health care professionals,
cancer control planners, and
policymakers.
The estimated annual burden hours
are as follows:
Product
Average
sample size
Frequency of
response
Average
duration
(hours)
Estimated
total burden
requested
(hours)
40 different products ........................................................................................
450
1
0.1
1800
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
For Further Information Contact: To
request more information on the
proposed project, contact Nina
Goodman, Senior Analyst, Office of
Communications and Education, NCI,
NIH, 6116 Executive Blvd., Suite 400,
Rockville, MD 20852, call non-toll-free
number 301–435–7789 or e-mail your
request to: goodman@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
rmajette on PROD1PC67 with NOTICES
Dated: February 7, 2007.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E7–2886 Filed 2–20–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
15:09 Feb 20, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Public Teleconference Regarding
Licensing and Collaborative Research
Opportunities for: PDE11A as a Novel
Therapeutic Target for Inherited Form
of Cushing Syndrome and Endocrine
Tumors; Dr. Constantine A. Stratakis et
al. (NICHD)
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
Technology Summary
The technology identifies a new form
of Cushing Syndrome, ‘‘isolated
micronodular adrenocortical disease’’
(iMAD), classified as a rare disease, as
well as the role of PDE11A gene in this
disease. We have identified particular
sequence variants of the PDE11A gene
causing abnormal or altered function of
this gene; these variants are present in
higher proportion in patients with
iMAD, as well as in patients with other
adrenal tumors. Additionally, we
suggest that PDE11A can be a potential
novel drug target for the treatment of
bilateral adrenal hyperplasia, and
possibly other endocrine tumors.
Technology Description
Phosphodiesterases (PDEs) are a
family of cyclic AMP (cAMP) and/or
cyclic GMP (cGMP)-hydrolyzing
enzymes that cleave 3′, 5′-cyclic
nucleotide monophosphates to 5′nucleotide monophosphates. The PDE
superfamily is large and complex,
containing 11 highly related and
structurally related gene families and
over 60 distinct isoforms. PDE family
members hydrolyze exclusively cAMP
(PDE4, PDE7, and PDE8), exclusively
cGMP (PDE5, PDE6, and PDE9), or both
cAMP and cGMP (PDE1, PDE2, PDE3,
PDE10, and PDE11). Specifically,
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
PDE11A is a dual-specificity
phosphodiesterase and is expressed in
several endocrine tissues including the
adrenal cortex. Members of the PDE
family differ in tissue distribution,
inhibitor specificity, and in mode of
regulation. The side effects of the PDE
inhibitors are contributed by the crossreactivity of the inhibitors to other
isoforms of the PDE.
The invention is the discovery that
the PDE 11A gene has statistically
significant linkage to ‘‘isolated
micronodular adrenocortical disease’’
(iMAD), an inherited form of Cushing
Syndrome. Patients suffering from the
disease have high cortisol levels and
infants with this disease may die from
related complications, e.g., malignant
hypertension or immunosuppression.
So far the inventors have identified 3
inactivating mutations of an isoform of
the PDE 11A gene, PDE11A4 linked to
this particular form of Cushing
syndrome; they have also identified
several sequence polymorphisms of this
gene that may be associated with a
variety of adrenal and other conditions.
One of these polymorphic variations of
the sequence that have been identified
leads to an alternate protein product of
the PDE11A4 isoform. Such
polymorphisms may have important
implications for drugs that depend that
depend on PDEs functions.
The invention can be separated into
three categories:
1. Clinical identification of a new
disease termed ‘‘isolated micronodular
adrenocortical disease’’ (iMAD), an
inherited form of Cushing Syndrome.
2. Identification of PDE11A gene and
sequence variants for the diagnosis of
‘‘isolated micronodular adrenocortical
disease’’ (iMAD) a form of Cushing
Syndrome and endocrine tumors, i.e. as
diagnostic genetic biomarker.
3. Identification of PDE11A as a
potential novel drug target for the
treatment of bilateral adrenal
hyperplasia and other endocrine and
E:\FR\FM\21FEN1.SGM
21FEN1
]]>Agencies
[Federal Register Volume 72, Number 34 (Wednesday, February 21, 2007)]
[Notices]
[Pages 7894-7895]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-2886]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; Customer Satisfaction With
Educational Programs and Products of the National Cancer Institute
Summary: In compliance with the requirement of Section
3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity
for public comment on proposed data collection projects, the National
Cancer Institute (NCI), the National Institutes of Health (NIH) will
publish periodic summaries of proposed projects to be submitted to the
Office of Management and Budget (OMB) for review and approval.
Proposed Collection
Title: Customer Satisfaction with Educational Programs and Products
of the National Cancer Institute.
Type of Information Collection Request: EXTENSION
(OMB0925-0526, expires 2/28/07).
Need and Use of Information Collection: The Office of
Communications and Education (OCE) of the National Cancer Institute
(NCI) is responsible for the design, implementation, and evaluation of
education programs over the entire cancer continuum, including
prevention, screening, diagnosis, treatment, survivorship, and
palliative care; it also manages NCI initiatives that address specific
challenges in cancer research and treatment. To help ensure the
relevance, utility, and appropriateness of the many educational
programs and products that OCE and NCI produce, OCE intends to collect
information on customer
[[Page 7895]]
satisfaction with those products through customer satisfaction surveys.
By obtaining information from customers on the extent to which
materials satisfy their needs, OCE and NCI will be able to
systematically establish and follow a feedback loop that provides
useful information to revise and enhance educational programs and
products so that they attain maximum relevance, utility,
appropriateness, and impact. Data will be collected through various
means, including telephone, mail, in-person, and web-based surveys.
Frequency of Response: On occasion.
Affected Public: Individuals or households, organizations involved
in providing health care services.
Type of Respondents: Health care consumers of NCI educational
programs or products, including cancer patients and families, health
care professionals, cancer control planners, and policymakers.
The estimated annual burden hours are as follows:
----------------------------------------------------------------------------------------------------------------
Estimated total
Average sample Frequency of Average burden
Product size response duration requested
(hours) (hours)
----------------------------------------------------------------------------------------------------------------
40 different products....................... 450 1 0.1 1800
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) Ways to minimize
the burden of the collection of information on those who are to
respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
For Further Information Contact: To request more information on the
proposed project, contact Nina Goodman, Senior Analyst, Office of
Communications and Education, NCI, NIH, 6116 Executive Blvd., Suite
400, Rockville, MD 20852, call non-toll-free number 301-435-7789 or e-
mail your request to: goodman@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Dated: February 7, 2007.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. E7-2886 Filed 2-20-07; 8:45 am]
BILLING CODE 4140-01-P
